// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Outcomes of IBD patients treated with infliximab: The impact of therapeutic drug monitoring in real-life clinical practice

N Kamperidis - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Infliximab

A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration

A Rowley - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Improvements in subcomponents of the inflammatory bowel disease questionnaire in patients treated with vedolizumab: Results from GEMINI trial data

D T Rubin - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Entyvio

Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)

S S R Pulusu - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Health-related utility weights in Crohn's disease patients with perianal fistula

L Longworth - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Dermatological reactions associated with anti–TNF therapy in inflammatory bowel disease- an 12 year experience

A Bhandare - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Adalimumab

Vedolizumab therapy results in reduced hospitalisation and steroid use over 1-year: Results from the Scottish vedolizumab consortium

N Plevris - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Entyvio

Efficacy of vedolizumab in patients with Crohn's disease may differ depending on the disease location: The UCLH experience

T Kumagai - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Persistent mesorectal inflammatory activity is associated with complications after proctectomy in Crohn’s disease

E J de Groof - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Colectomy-free survival and factors associated with it in children with ulcerative colitis managed in a tertiary IBD centre in the UK

S -Y Ong - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Systematic review: Psychosocial factors associated with pain in inflammatory bowel disease

L Sweeney - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Comparative efficacy on steroid-free remission of pharmacological therapies for moderate-to-severe ulcerative colitis: A systematic review and network meta-analysis

P Paschos - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Entyvio

Development of a model of 3D imaging for the pre-operative planning of TaTME

K Sahnan - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Methadone hydrochloride

Development of an index that predicts escalation of therapy at an outpatient appointment in patients with known ulcerative colitis (UC)

A Walsh - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Is liver steatosis a risk factor for hepatotoxicity in patients with inflammatory bowel disease on thiopruines?

J Phillips - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Oraprine

Patient and public involvement in a clinical trial for perianal Crohn’s fistula

K Sahnan - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Double assessment of ileal pouch-anal anastomosis before ileostomy reversal

A Gklavas - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

N/A

N/A

Biological interventions for induction and maintenance of mucosal healing in ulcerative colitis: A Cochrane systematic review

A Ricciuto - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease

S Travis - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Entyvio

Real-world evidence (RWE) on outcomes and clinical treatment patterns of 5-aminosalicylic acid (5-ASA) in mild Crohn’s disease (CD) from European healthcare databases (the CROHN’S investigation)

K Paridaens - European Crohn’s and Colitis Organisation (ECCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

Mesalamine

Copyright © 2026. QuantiNova All rights reserved